RPID
NASDAQ · Life Sciences Tools & Services
Rapid Micro Biosystems Inc-A
$0.67
-0.08 (-10.19%)
Financial Highlights (FY 2026)
Revenue
38.65M
Net Income
-54,222,484
Gross Margin
3.1%
Profit Margin
-140.3%
Rev Growth
+25.2%
D/E Ratio
0.57
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 3.1% | 3.1% | 67.1% | 67.1% |
| Operating Margin | -141.1% | -127.0% | 15.2% | 14.6% |
| Profit Margin | -140.3% | -133.3% | 15.7% | 16.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 38.65M | 30.88M | 48.80M | 45.04M |
| Gross Profit | 1.21M | 963.3K | 32.74M | 30.22M |
| Operating Income | -54,528,308 | -39,210,192 | 7.43M | 6.55M |
| Net Income | -54,222,484 | -38,990,280 | 7.65M | 7.46M |
| Gross Margin | 3.1% | 3.1% | 67.1% | 67.1% |
| Operating Margin | -141.1% | -127.0% | 15.2% | 14.6% |
| Profit Margin | -140.3% | -133.3% | 15.7% | 16.6% |
| Rev Growth | +25.2% | +25.2% | +18.7% | +19.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 5.87M | 5.87M | 38.69M | 38.35M |
| Total Equity | 10.21M | 10.21M | 134.82M | 132.50M |
| D/E Ratio | 0.57 | 0.57 | 0.29 | 0.29 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -50,788,273 | -38,549,743 | 9.93M | 10.62M |
| Free Cash Flow | — | — | 5.64M | 3.34M |